Sana Biotechnology
Sana Biotechnology develops engineered cell and gene therapies to repair, control, or replace cells in order to address the underlying causes of diseases such as diabetes, B-cell cancers, and B-cell related autoimmune disorders. Its mission is to create novel medicines that meaningfully improve patient outcomes and broaden access to transformative treatments.
Facts
- Sectors
- Biotechnology, Gene editing, Cell therapy, Biopharmaceuticals
- Founded
- 2018 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Sana Biotechnology Inc Seattle business license
- Stage
- Public
- Members see funding amounts. .
Is this your organization? Claim it
Sana Biotechnology Advances SC451 and SG293 Toward Clinical Trials, NEJM UP421 Follow-up; Q3 Cash $121.7M, Runway Into Mid‑2027
Sana Biotechnology reports Q3 2026 progress toward initiating SC451 Phase 1/2 for type 1 diabetes and a clinical study for SG293 in non-Hodgkin lymphoma, advancing collaborations with Mayo Clinic and publishing long-term UP421 hypoimmune islet transplant data in NEJM. The company expects to start a study of SG227 for multiple myeloma as early as 2027 and holds $121.7 million in cash, projecting runway into mid-2027.
Yoodli launches AI platform to build courses, coach employees and track workplace skill gains after $300M+ valuation
Yoodli is expanding from AI practice sessions for public speaking into an “AI platform for human skills” that builds training courses, coaches employees during meetings, answers workplace questions, and tracks skill improvement. The startup—valued at over $300 million in December and backed with nearly $60 million from investors—aims to move into corporate training alongside firms like Workday and LinkedIn.
Life Science Washington, Arzeda Host NSCEB Commissioners in Seattle to Press for $15B Federal Boost and Policy Changes to Shore Up U.S. Biotech Competitiveness
Life Science Washington and Arzeda hosted NSCEB commissioners in Seattle to showcase the region’s biotech strengths and discuss federal policy, emphasizing needs for research funding, capital access, scale-up capacity, AI-enabled infrastructure, and workforce development to bolster U.S. biotech competitiveness against China.
See all 59 news stories about Sana Biotechnology.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Steve Harr Co-founder and President and Chief Executive Officer
-
Snehal Patel Executive, Executive Vice President and Chief Technical Officer